Rosiglitazone in Combination With Glimepiride Plus Metformin in Type 2 Diabetic Patients (original) (raw)

Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes

Mehmet Sargin

Endocrine Journal, 2004

View PDFchevron_right

Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

Poul Strange

Diabetes Care, 2006

View PDFchevron_right

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial

Arrigo Cicero

Diabetes, Obesity and Metabolism, 2006

View PDFchevron_right

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

Byron Hoogwerf

The Lancet, 2006

View PDFchevron_right

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

Philip Raskin

Diabetologia, 2000

View PDFchevron_right

Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone

J. McGill

Diabetic Medicine, 2004

View PDFchevron_right

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

Juan Barbosa

Diabetes-metabolism Research and Reviews, 2002

View PDFchevron_right

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

Luc Van Gaal

Diabetes, Obesity and Metabolism, 2003

View PDFchevron_right

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Nigel Jones

The Lancet, 2009

View PDFchevron_right

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes

Lucio Vilar

Arquivos Brasileiros de Endocrinologia & Metabologia, 2010

View PDFchevron_right

Antithrombotic Effects of Rosiglitazone-Metformin versus Glimepiride-Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

Arrigo Cicero

Pharmacotherapy, 2005

View PDFchevron_right

A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes

Philip Raskin

Diabetes Care, 2001

View PDFchevron_right

Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy

Julius Vaz

Clinical Therapeutics, 2003

View PDFchevron_right

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Barbara Kravitz

Diabetes, Obesity and Metabolism, 2006

View PDFchevron_right

Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes

Dimitrios Karamitsos

In vivo (Athens, Greece)

View PDFchevron_right

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis

Arvind Agrawal

Clinical Therapeutics, 2003

View PDFchevron_right

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes

Alptekin Gursoy

Acta Diabetologica, 2007

View PDFchevron_right

Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

mustafa noor

American Journal of Medicine, 2004

View PDFchevron_right

The Effect of Rosiglitazone on Liver in Type 2 Diabetes Patients

Jitendra Ahuja

International journal of current research and review, 2013

View PDFchevron_right

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

Arvind Agrawal

Diabetic Medicine, 2004

View PDFchevron_right

Rosiglitazone reduces urinary albumin excretion in type II diabetes

George Bakris

Journal of Human Hypertension, 2003

View PDFchevron_right

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

mark jonh

… England Journal of …, 2006

View PDFchevron_right

Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin

Arrigo Francesco Giuseppe Cicero

Archives of Medical Research, 2008

View PDFchevron_right